Human Monoclonal Antibodies to Epidermal Growth Factor Receptor

Details for Australian Patent Application No. 2004231235 (hide)

International Classifications

Event Publications

9 December 2004 Complete Application Filed

23 December 2004 Application Open to Public Inspection

Published as AU-A-2004231235

9 February 2006 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 11 Jan 2006

2 August 2007 Assignment before Grant

Abgenix, Inc. The application has been assigned to Amgen Fremont Inc.

5 June 2008 Application Accepted

Published as AU-A-2004231235

8 October 2009 Standard Patent Sealed

1 April 2010 Extension of Term of Standard Patents

Amgen Fremont Inc. The earliest first regulatory approval date provided by the patentee 23 May 2008 For the goods VECTIBIX panitumumab

3 June 2010 Extension of Term of Standard Patents

Amgen Fremont Inc. The earliest first regulatory approval date provided by the patentee 14 May 2008 For the goods VECTIBIX panitumumab Address for service in Australia: Cullens Patent and Trade Mark Attorneys Level 32 239 George Street Brisbane QLD 4000

28 October 2010 Extension granted

Amgen Fremont Inc. The earliest first regulatory approval date provided by the patentee 14 May 2008 For the goods VECTIBIX panitumumab Extension of Term of patent pursuant to Section 77 expires on 05 May 2023

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.